THE NEXT
EVOLUTION IN
CELLULAR
MEDICINE
Celularity is a biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells (ASCs), targeting indications across cancer, immunologic, infectious, and degenerative diseases.
BEST IN CLASS & SCALABLE
Cellular Medicine manufacturing
Featuring industry leading and diverse product lines
ALLOGENEIC PLATFORM
Built on two decades of science
Driven by a deep, seasoned management team
OUR MISSION
is to lead the next evolution in cellular medicine by delivering off-the-shelf allogeneic cellular therapies, at unparalleled scale, quality, and economics

OUR VISION
Harness the Unique Biology & Ready Availability of the Placenta
- Unmet Global NeedSignificant unmet global need for allogeneic cellular medicines delivered on-demand, off-the-shelf
- Groundbreaking ResearchGroundbreaking basic & translational research into the unique biological activity of placental-derived cells
- Pioneering TechnologyPioneering technology platform of placental-derived cellular medicines and advanced biomaterials
- Industry TimingThe time has arrived for cellular medicines that overcome barriers of scale, quality, and economics
Cellular Medicine Manufacturing
The Process is the Product
A fully integrated, purpose-built manufacturing, translational research and biobanking center
- Purpose-built facility staffed by over 100 highly specialized scientists, engineers & technicians
- 150,000 sq ft including laboratory and advanced manufacturing space for cellular medicine & biomaterials
- Clinical Scale – (9) Grade C/ISO 7 suites and (6) Grade D/ISO 8 labs ALL GMP-CAPABLE
The Latest From Our
NEWSROOM
Celularity Inc. expansion is driven by experienced Cellular Medicine leaders & innovators with deep expertise in clinical development & regulatory approval.
Celularity Appoints Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of Directors
Celularity Announces Multi-Year Research Collaboration Services Agreement With Regeneron
Letter to shareholders
Celularity Inc. Announces $3 Million Registered Direct Offering